B rugada syndrome (BrS) is characterized by right precordial ST elevation, susceptibility to ventricular arrhythmias, and sudden cardiac death. 1,2 Because the SCN5A gene, which codes for cardiac voltage-gated sodium channels, was reported to be a causative gene of BrS, 3 many other susceptibility genes have been identified. 4 Among them, the SCN5A gene accounts for the vast majority of cases.
Protective Effect of HEY2 Gene in Brugada Syndrome
to 13% of Brugada probands. 6 Mutations in the other causative genes are rare, such as those in GPD1L (BrS2), SCN1B (BrS5), KCNE3 (MiRP2, BrS6), SCN3B (BrS7), KCNJ8 (BrS8), KCND3 (BrS10), MOG1 (BrS11), and KCNE5 (BrS12). 7 Despite the advances in our understanding of the genetics of the disorder, many patients with BrS do not have a genetic explanation, and the genetic testing is not involved in the diagnosis of BrS. 8, 9 In a recent genome-wide association study (GWAS), 3 single-nucleotide polymorphisms (SNPs) were reported to be associated with BrS. 10 These SNPs were in SCN5A (rs11708996; G>C located intronic to SCN5A), SCN10A (rs10428132; T>G located in SCN10A), and HEY2 (rs9388451; T>C located downstream of HEY2). The HEY genes encode a small family of basic helix-loop-helix (belch) proteins that act as transcriptional repressors downstream of the Notch signaling and are important for cardiovascular development. 11, 12 However, the clinical relevance of these SNPs in BrS, especially the relationship between the ventricular fibrillation (VF) risk and SNP genotypes, has not yet been completely elucidated. Therefore, we investigated these 3 SNPs in Japanese patients together with the relationship between the risk allele and the symptoms of BrS.
Methods

Participants
We enrolled a total of 95 patients with BrS (89 males and 6 females; mean age, 43±16 years) from Hiroshima University Hospital. We also enrolled 1978 controls (1546 males and 452 females; mean age, 54±18 years) from Hiroshima University Hospital. All participants were unrelated Japanese individuals. For a diagnosis of BrS, the patients were required to have ST-segment elevation with a type 1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of structural heart disease. 13 The Institutional Ethics Committee of the Graduate School of Biomedical Science at Hiroshima University approved all procedures involving human tissue usage. Written informed consent was obtained from all participants.
Sequence Analysis of SCN5A and Genotyping
Peripheral blood was obtained from all the participants. Genomic DNA was extracted from leukocytes using a QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the standard protocol. Using Go Taq (Promega, Madison, WI), all coding regions of SCN5A were amplified by a polymerase chain reaction (PCR) from 2.5 ng of genomic DNA, using our original primers. Only 74 genomic DNA samples out of 95 could be sequenced because of the small amount of template DNA. These amplified coding regions were then sequenced using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA) to identify mutations and polymorphisms. Subsequently, we genotyped rs10428132 of SCN10A, rs11708996 of SCN5A, and rs9388451 downstream of HEY2 in all participants using the Taq Man assay, as described previously. 14, 15 As for typing of rs9388451, we used forward primer: GCTGCTACTTCATCTTCCTTGC and reverse primer: GAAGGAACATGTGCAAGGCCTT. We used Invader oligo: GGATCTTGCATGGCCTCGTAGTGAGGTGAT, signal prove-C: cgcgccgaggGGGATTTTGTCTTCACACTAA, and signal prove-T: atgacgtggcagacAGGATTTTGTCTTCACACTAAG.
Twelve-Lead ECG Findings
The 12-lead ECG was recorded at a paper speed of 25 mm/s and an amplification of 1 cm/mV. We measured the RR, PQ, QRS, and corrected QT (QTc) intervals in lead V 6 and the J-point amplitude in leads V 1 and V 2 (STJ). We classified the Brugada ECG patterns into types 1 through 3 according to the criteria of the BrS consensus conference. 13 Because the ST configurations in the right precordial leads are known to have a day-to-day variation, more than 5 ECGs were recorded on different days. A type 1 Brugada ECG pattern was diagnosed when the pattern was recorded spontaneously on at least 1 occasion. We calculated mean intervals of the RR, PQ, QRS, and QTc intervals of all recorded ECGs. We also recorded the 12-lead ECG in 103 of the normal controls and measured the RR, PQ, QRS, and QTc intervals.
Signal-Averaged ECG Findings
Late potentials were analyzed using an FP-705LP (Fukuda Denshi, Tokyo, Japan). The ECG was recorded using Frank X, Y, and Z leads during sinus rhythm, and signals from 300 beats were amplified, digitized, averaged, and filtered with backward and forward filters at a high-band pass frequency of 40 Hz. The total filtered QRS (f-QRS) duration, root mean square voltage of the terminal 40 ms of the f-QRS, and duration of the low-amplitude signals of <40 μV in the terminal f-QRS duration were calculated. Late potentials were identified as being present when 2 of the following criteria were satisfied: an f-QRS >114 ms, root mean square voltage of the terminal 40 ms of the f-QRS duration <20 μV, or duration of the low-amplitude signals of <40 μV in the terminal f-QRS duration >38 ms. 16 We recorded the signal-averaged ECG more than 2 times and calculated the mean of the all recordings.
Electrophysiological Study
The patients underwent an electrophysiological study. Three 5-French-gage quadripolar electrode catheters, each with a 5-mm inter-electrode distance, were positioned at the high right atrium, His bundle, and right ventricle. The AH and HV intervals were measured on the baseline ECG. The sinus node recovery time and atrioventricular node effective refractory period were also determined.
WHAT IS KNOWN
• Risk stratification of Brugada syndrome (BrS) remains controversial. The SCN5A gene was reported to be a main causative gene of BrS, but the majority of BrS have not been genetically determined.
• The single-nucleotide polymorphism (SNP) of HEY2 gene (rs9388451; T>C located downstream of HEY2) was reported to be associated with BrS in a recent genome-wide association study.
WHAT THE STuDy ADDS
• The HEY2 SNP (rs9388451) was associated with BrS in 95 Japanese BrS, but risk allele C was significantly less frequent in BrS patients with VF than in those without. During 63±28 months follow-up periods after ICD implantation, the cumulative rate of VF events was significantly lower in cases with HEY2 CC genotype.
• HEY2 mRNA expression level in the right ventricular specimens from patients with BrS was significantly lower in patients with CC genotype than the other genotypes, and QTc was linearly increased with the number of C allele. Our findings suggest that HEY2 CC genotype may be a prognostic marker for BrS, protectively acting to prevent VF presumably by regulating the repolarization current. Protective Effect of HEY2 Gene in Brugada Syndrome
RNA Isolation and Quantitative Reverse Transcription PCR
Transverse sections of the septum of the right ventricular outflow tract were obtained by biopsy from 21 BrS subjects to exclude any diagnosis of arrhythmogenic right ventricular cardiomyopathy. The total RNA was isolated from the right ventricular sections using an AllPrep DNA/RNA/miRNA universal kit (QIAGEN). One specimen out of 21 was too small; we could not obtain a sufficient amount of RNA, and we analyzed 20 RNA samples.
From each sample, 1 μg of the total RNA was reverse transcribed to generate cDNA using the Super Script III Reverse Transcriptase (Invitrogen Corp, Carlsbad, CA). The RNA, in a 50 μM Oligo dT and 10 mM dNTP mixture, was heated at 65°C for 5 minutes and incubated on ice. We added a cDNA synthesis mix (10× reverse transcription buffer, 25 mM MgCl 2 , 0.1 M dithiothreitol, RNase OUT [Invitrogen, Carlsbad, CA], and Superscript III Reverse Transcriptase) to the mixture samples and incubated them at 50°C for 50 minutes and 85°C for 5 minutes. Quantitative reverse transcription PCR of the HEY2 mRNA was performed using a CFX384 Touch real time-PCR system (Bio-Rad, Pleasanton, CA). We used GAPDH as a reference gene and 1 μL of the cDNA for the PCR mixture (SYBR Premix Dimer Eraser [TAKARA, Japan]) containing 0.3 μmol of the original specific primers. Initial denaturation at 95°C for 30 s was followed by amplification, involving 39 cycles with denaturation at 95°C for 5 s, annealing at 55°C for 30 s, and elongation at 72°C for 30 s. The GAPDH cDNA was used as a control. Primer sequences used were HEY2, 5′-TTGAAGATGCTTCAGGCAACAGGG-3′ and 5′-TCAGGTACCGCGCAACTTCTGTTA-3′, and GAPDH, 5′-GTCTC CTCTGACTTCAACAGCG-3′ and 5′-ACCACCCTGTTGCTGTA GCCAA-3. Data analysis was performed with CFX manager (Bio-Rad).
Statistical Analysis
Normally distributed continuous variables are presented as the mean±standard deviation. The continuous data between the 2 groups were analyzed using the nonparametric Mann-Whitney U test. The differences among the 3 genotypes were analyzed by a linear regression for continuous data. Odds ratios (OR) and 95% confidence intervals are stated as appropriate. To test the genetic associations between the cases and controls, we used the χ 2 test and the Cochran-Armitage trend test. Deviation from the Hardy-Weinberg equilibrium was tested among the cases and controls using an ordinary χ 2 test, where a P value of <0.05 was considered significant. We used the Breslow-Day test to test for homogeneity of the OR in the 2 populations. Then we calculated the combined P value by using meta-analysis methods. Mantel-Haenszel test was applied and the combined P value. Event-free survival curves after implantable cardioverter defibrillator implantations were constructed using the Kaplan-Meier method and compared using the log-rank test.
Results
Relationship Between the GWAS-Identified SCN10A (rs10428132) and HEY2 (rs9388451) SNPs in the BrS Cases and Controls
The results of HEY2, SCN10A, and SCN5A genotyping are shown in Tables 1 and 2. The risk alleles of HEY2 (rs9388451, C>T) and SCN10A (rs10428132, G>T) significantly increased the risk of BrS (HEY2: OR, 1.7; P=9.2×10 −4 and SCN10A: OR, 3.0; P=2.7×10 −14 ) . There was no relationship between the GWAS reported SCN5A SNP (rs11708996) and BrS in our study.
Surprisingly, the HEY2 C allele was more frequent in the BrS patients without VF than in those with VF, suggesting a protective effect of this allele against VF occurrence (Table 3; 74% versus 59%; OR, 0.5; P=0.04). We also examined the relationship between the HEY2 allele and symptoms of BrS using our data and that of the GWAS Japanese database. 10 The Breslow-Day test showed no heterogeneity (P=0.39) between our data and the GWAS data, 10 and the overall degree of association by the Mantel-Haenszel test was significant (OR, 0.6; P=0.02; Table 4 ).
In contrast, the frequency of the SCN10A risk allele was similar in the BrS patients with and without VF. The PQ interval was longer in patients with the SCN10A risk allele than in those without the SCN10A risk allele as previously reported (CC, 157±2.5 ms; CT, 172±5.3 ms; TT, 172±3.5 ms; P=1.8×10 −3 ), but the SCN10A SNP was not associated with the clinical severity of BrS. Table 5 shows the relationship between the clinical characteristics, 12-lead ECG findings, signal-averaged ECG findings, and electrophysiological study parameters and the HEY2 genotype in the patients with BrS. The age and sex were similar among the HEY2 genotypes. The frequency of the VF history was lower in patients with the HEY2 C risk allele than in those with the other genotypes (CC, 25%; CT, 25%; TT, 63.6%; P=4.1×10 −2 ). A significant linear correlation was found between HEY2 genotypes and QTc interval (CC, 422±27 ms; CT: 408±21 ms, TT: 381±27 ms, P=4.0×10 −4 ). The other parameters of the ECG, signal-averaged ECG, and electrophysiological study were not related to the HEY2 genotypes. The QTc interval was also longer in the controls with the CC genotype than in those with the other genotypes (Table 6 ; CC, 417±19 ms; CT, 402±21 ms; TT, 400±20 ms; P=1.4×10 −3 ).
HEY2 Genotypes and a VF History in BrS Cases
We found 6 mutations within SCN5A in 74 patients with BrS (8.1%), and of these, 4 were missense mutations (H278R[Ex7:DI-S5/S6], N782T [Ex15:DII-S3], G1420R [Ex 24: DIII-S5/S6], and E1784K [Ex28:C terminal]), 1 was an in-frame deletion mutation (N740 del [Ex14:DII-S1/S2]), and one was a splice-site mutation (3840 + 1 G>A [Intron 21]). The HEY2 rs9388451 CC, CT, and TT genotypes were distributed similarly in the patients with and without the SCN5A mutation. The patient with E1784K possessed the HEY2 CC genotype and did not experience VF. 
HEY2 Genotypes and Subsequent VF Events in BrS Cases
During a mean follow-up of 63±28 (range, 12-132) months after the implantable cardioverter defibrillator implantation, VF occurred in 12 patients. The Kaplan-Meier event-free survival curves after the implantable cardioverter defibrillator implantation revealed that the rate of VF events was significantly lower in the cases with HEY2 CC genotype than in those with the other genotypes using the log-rank test (P=0.04; Figure 1 ).
Relationship Between the HEY2 Genotypes and Expression Levels of HEY2
Among the 20 patients who underwent the right ventricular biopsy, the distribution of the HEY2 rs9388451 CC, CT, and TT genotypes was 10 (47.6%), 9 (42.7%), and 1 (4.8%), respectively. The expression level of HEY2 mRNA was lower in the patients with the CC genotype than in those with the other genotypes (P=0.04; Figure 2 ).
Discussion
In this study of 95 Japanese patients with BrS and 1978 healthy controls, we replicated the association of SCN10A (rs10428132) and HEY2 (rs9388451) with BrS reported in the recent GWAS. 10 However, despite being identified as a risk locus for BrS in the GWAS, the HEY2 C allele was notably more frequent in cases without VF than in those with VF, suggesting that it may provide some protection against VF in Japanese patients with BrS. Additionally, a significant linear correlation was found between HEY2 genotypes and QTc interval, and the QTc interval increased with increased possession of the HEY2 C allele. Furthermore, the HEY2 expression was lower in the patients with the CC genotype than the other genotypes.
The HEY2 SNP work is significant in CC versus CT+TT genotype when comparing BrS with controls and also when comparing BrS with and without VF. As for the subsequent VF events, event-free periods were also significant in patients with CC versus those with CT+TT. However, with respect to QTc of BrS, additive genetic model seems to be the best, indirectly suggesting an additive linear model for HEY2 expression. Unfortunately, we could not examine which genetic model is the best fitting model for expression levels of HEY2 because of limited numbers of cardiac samples of BrS available.
BrS is a heritable arrhythmia syndrome associated with sudden death, typically among young male adults; however, its penetrance is incomplete, and it has variable expressivity characteristics. Since the association between SCN5A and BrS was first reported, 3 a lot of SCN5A mutations have been identified, 5 with loss-of-function SCN5A mutations being the primary genetic cause of BrS. Despite this fact, such mutations account for only about 20% of clinical BrS. Overall, mutations in SCN5A and other causal genes 4 occur in just one third of all cases of BrS, suggesting that other genetic factors are yet to be identified.
We confirmed that SCN10A (rs10428132) and HEY2 (rs9388451) were associated with BrS. More importantly, we also demonstrated that the HEY2 (rs9388451) C allele was more frequent in cases without VF than in those with VF. In the GWAS paper, they investigated relationship between the HEY2 genotype and symptomatic/asymptomatic BrS, and there was no significant difference between the 2 groups. 10 The different results may be because the symptomatic group in the GWAS data included not only VF history but also a history of syncope. However, when we included the data of Japanese patients with BrS from the GWAS paper, 10 the association between the HEY2 genotype and VF in the patients with BrS became stronger. Furthermore, the frequency of a VF history was lower in the patients with the CC and CT genotypes than in those with the TT genotype. In contrast, the tendency in European population may not be similar to ours because the Breslow-Day test showed significant heterogeneity (P=0.04, data not shown). The reason for the discrepancy is unclear. It may suggest the possible presence of populationspecific modifier genes or other factors, working with HEY2 C allele to protect VF in patients with BrS. This is an important The T allele was considered as the reference allele. The risk allele C of HEY2 SNP rs9388451 was less frequent in the BrS patients with VF than in those without VF, suggesting a protective effect of this allele against VF occurrence (74% vs 59%; OR, 0.5; P=0.04). BrS indicates Brugada syndrome; CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism; and VF, ventricular fibrillation. Protective Effect of HEY2 Gene in Brugada Syndrome point and should be explored to strengthen our findings. However, unfortunately, we could not access further information of large-scale data by Bezzina et al. 10 Further functional studies as well as replication studies in various populations with a larger sample size are needed to confirm the relevance of our findings. The HEY2 SNP genotype distributions in BrS with VF and BrS without VF of our study and those of the Japanese population derived from previous GWAS were shown. Mantel-Haenszel test was applied, and the combined P value for independence was 0.02 (OR, 0.6).The T allele was considered as the reference allele. BrS indicates Brugada syndrome; CI, confidence interval; GWAS, genome-wide association study; OR, odds ratio; Phet, heterogenity P; SNP, single-nucleotide polymorphism; and VF, ventricular fibrillation.
* Quantitative data were expressed as mean±SD. Binary variables were compared by χ 2 test under the allelic model, and quantitative traits were tested for association by linear regression. The frequency of the VF history was lower in patients with the HEY2 C risk allele than in those with the other genotypes. A significant linear correlation was found between HEY2 genotypes and QTc interval. AVN indicates atrioventricular node; EPS, electrophysiological study; f-QRSd, filtered QRS duration; LAS, low-amplitude signals; LP, late potential; RMS, root mean square; SNRT, sinus node recovery time; % SRT, SNRT/sinus cycle length; and VF, ventricular fibrillation. Protective Effect of HEY2 Gene in Brugada Syndrome
In the Kaplan-Meier analysis of the event-free survival among the 90 patients who underwent implantable cardioverter defibrillator implantations, a significantly lower incidence of VF events was observed in cases with the HEY2 CC genotype. Although the risk stratification for VF in patients with BrS remains challenging and controversial, the result of the Kaplan-Meier analysis may suggest that the HEY2 (rs9388451) genotype may be important for the future risk stratification of BrS. In contrast, despite the greater effect size of the SCN10A variant compared with HEY2, the frequency of SCN10A (rs10428132) was similar in cases with and without VF (the Kaplan-Meier analysis showed no difference, data not shown).
The HEY genes encode a small family of basic helix-loophelix (belch) proteins that act as transcriptional repressors downstream of the Notch signaling and are important for cardiovascular development. HEY1 expresses in the atrial portion, and HEY2 is restricted to the ventricular portion. 11, 12 Specifically, Hey 2-knockout mice exhibit various cardiac impairments, including ventricular septal defects, valvular abnormalities, cardiac hypertrophy, and fatal cardiomyopathy. 17, 18 Other reports demonstrate that the ectopic activation of atrial genes in the ventricular myocardium 19 and that HEY2 promotes proper ventricular myocardial maturation. 20, 21 Although Hey 2 +/− mice have structurally normal hearts, the conduction velocity and action potential uptake velocity are significantly increased in the right ventricular outflow tracts of their hearts. 10 In addition, the repolarization parameters are prolonged, suggesting the influence of HEY2 on repolarization. 10 Another recent paper reported that cardiomyocytes from Hey2-knockout mice showed an increased delay after repolarization. 22 In this study, the QTc interval increased as the number of the HEY2 C allele increased, and it was significantly longer in cases with CC and CT genotypes than TT genotype. This is consistent with the previous data suggesting a relation between the HEY2 gene and cardiac repolarization. It was also reported that cardiomyocytes from Hey2-knockout mice demonstrated a 50% to 75% reduction in expression of the SCN5A, KCNJ2, and CACNA1C ionchannel subunit genes, suggesting that HEY2 is related to the pathogenesis of BrS through the expression of SCN5A and the cardiac conduction system. 22 In our study, using reverse transcription PCR, we clarified that the expression levels of HEY2 were lower in patients with the HEY2 CC genotype than in those with the other genotypes. The result suggested that HEY2 expression may directly be related to cardiac repolarization, and the observation that the lengths of the QTc intervals differed among the HEY2 alleles is consistent with that suggestion.
The HEY2 C allele (rs9388451) was protective against VF, despite being identified as a risk for BrS in the GWAS. 10 We propose several hypotheses to explain this result. First, the real BrS-associated gene that is related to this HEY2 SNP could be rare and, therefore, was not detected by the GWAS Figure 1 . Kaplan-Meier Curve of Brugada syndrome patients by HEY2 Genotype. During mean 63±28 months of follow-up after ICD implantation, VF events occurred in 12 patients. The Kaplan-Meier event-free survival curves after ICD implantation revealed that the rate of VF events was significantly lower in cases with the HEY2 CC genotype than in those with the other genotypes. ICD indicates implantable cardioverter defibrillator; and VF, ventricular fibrillation. Quantitative data were expressed as mean±SD, Binary variables were compared by χ 2 test under the allelic model, and quantitative traits were tested for association by linear regression. A significant linear correlation between HEY2 genotypes and QTc interval was also found in controls. The QTc interval was longer in the controls with the CC genotype than in those with the other genotypes. Protective Effect of HEY2 Gene in Brugada Syndrome analysis. Second, the patients with both the HEY2 T allele and the causal gene have a short life span; therefore, the HEY2 C allele can accumulate in asymptomatic patients with BrS. Third, the association between the HEY2 allele and VF occurrence showed a racial difference that probably results from the degree of linkage between rs9388451 and some other unknown causal SNP. However, a subsequent analysis of the gene function and expression is necessary to understand this mechanism.
Bezzina et al 10 reported that conduction velocity was significantly increased in the right ventricular outflow tract of murine Hey2 +/− heart. The conduction disturbance was known to contribute to the maintenance of VF. 23 Therefore, the conduction velocity may be maintained in BrS patients with HEY2 CC genotype. Taken together, modifications of both action potential and conduction velocity due to reduced HEY2 expression may be a possible mechanism of protective effect of HEY2 CC genotype on the risk of VF events in BrS, although further study is needed to clarify the mechanisms underlying these data.
The SNPs rs10428132 and rs6795970 in SCN10A are highly linked and associated with the conduction system, including the PR interval. 24 This is consistent with the results of our study, in which the SCN10A risk allele was more frequent in patients with BrS than in the controls; moreover, the allele was also associated with a longer PR interval.
In conclusion, the HEY2 SNP could be a useful prognostic marker for BrS, with its presence suggesting protection against VF occurrence, presumably through its role in regulating the repolarization current.
